These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 589882)
1. Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy. Sadee W; Wong CG Clin Pharmacokinet; 1977; 2(6):437-50. PubMed ID: 589882 [TBL] [Abstract][Full Text] [Related]
2. On the rational development of a new drug: the example of the fluorinated pyrimidines. Heidelberger C Cancer Treat Rep; 1981; 65 Suppl 3():3-9. PubMed ID: 7346154 [TBL] [Abstract][Full Text] [Related]
3. Sequential methotrexate and 5-fluorouracil: mechanisms of synergy. Bertino JR; Mini E; Fernandes DJ Semin Oncol; 1983 Jun; 10(2 Suppl 2):2-5. PubMed ID: 6867754 [TBL] [Abstract][Full Text] [Related]
4. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. Myers CE; Young RC; Chabner BA J Clin Invest; 1975 Nov; 56(5):1231-8. PubMed ID: 1184747 [TBL] [Abstract][Full Text] [Related]
5. Determinants of response to antimetabolites and their modulation by normal purine and pyrimidine metabolites. Rustum YM; Danhauser L; Luccioni C; Au JL Cancer Treat Rep; 1981; 65 Suppl 3():73-82. PubMed ID: 7049369 [TBL] [Abstract][Full Text] [Related]
6. [Biochemical modulation of 5-fluorouracil by high-dose leucovorin]. Aiba K Gan To Kagaku Ryoho; 1988 Mar; 15(3):392-408. PubMed ID: 3279911 [TBL] [Abstract][Full Text] [Related]
8. Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Grem JL; Fischer PH Cancer Res; 1986 Dec; 46(12 Pt 1):6191-9. PubMed ID: 2946402 [TBL] [Abstract][Full Text] [Related]
9. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Casale F; Canaparo R; Serpe L; Muntoni E; Pepa CD; Costa M; Mairone L; Zara GP; Fornari G; Eandi M Pharmacol Res; 2004 Aug; 50(2):173-9. PubMed ID: 15177306 [TBL] [Abstract][Full Text] [Related]
10. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Spears CP; Shahinian AH; Moran RG; Heidelberger C; Corbett TH Cancer Res; 1982 Feb; 42(2):450-6. PubMed ID: 6173112 [TBL] [Abstract][Full Text] [Related]
11. [The biochemical modulation of 5-fluorouracil by leucovorin]. Borner M; Brunner K Schweiz Med Wochenschr; 1991 Aug; 121(33):1149-56. PubMed ID: 1925442 [TBL] [Abstract][Full Text] [Related]
12. [In vivo distribution and activation of 5-FU--with special reference to biochemical modulation of intracellular metabolism]. Fujita H Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):996-1002. PubMed ID: 3389839 [TBL] [Abstract][Full Text] [Related]
13. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Berger SH; Hakala MT Mol Pharmacol; 1984 Mar; 25(2):303-9. PubMed ID: 6608049 [TBL] [Abstract][Full Text] [Related]
14. Non-linear pharmacokinetics of 5-fluorouracil as described by in vivo behaviour of 5,6 dihydro-5-fluorouracil. de Bruijn EA; Remeyer L; Tjaden UR; Erkelens C; de Brauw LM; van de Velde CJ Biochem Pharmacol; 1986 Aug; 35(15):2461-5. PubMed ID: 3741455 [No Abstract] [Full Text] [Related]
15. Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. Derissen EJ; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH J Pharm Biomed Anal; 2015 Jun; 110():58-66. PubMed ID: 25804433 [TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718 [TBL] [Abstract][Full Text] [Related]
17. Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil. Washtien WL; Santi DV Cancer Res; 1979 Sep; 39(9):3397-404. PubMed ID: 157805 [TBL] [Abstract][Full Text] [Related]
18. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes. Liao ZY; Sordet O; Zhang HL; Kohlhagen G; Antony S; Gmeiner WH; Pommier Y Cancer Res; 2005 Jun; 65(11):4844-51. PubMed ID: 15930305 [TBL] [Abstract][Full Text] [Related]
19. [Clinical pharmacology of anticancer agents (Part 4). Antimetabolites (1)]. Nakamura T; Uchida M; Ueda T Gan To Kagaku Ryoho; 1992 Feb; 19(2):265-76. PubMed ID: 1736842 [TBL] [Abstract][Full Text] [Related]
20. The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. Finan PJ; Chisholm EM; Woodhouse L; Giles GR Eur J Surg Oncol; 1987 Aug; 13(4):349-53. PubMed ID: 2957234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]